CIK 0002023658 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Bicara Therapeutics Inc.
Sign in to watch- Ticker
- BCAX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-468-4219
- Business address
- 116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $400,716
- in 1 filing, $401K under 10b5-1 plans
Net −$400,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-13 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +11,445 | $3.79 | $43K | 321,337 |
| 2025-10-13 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 | −11,445 | $18.92 | $217K | 309,892 |
| 2025-10-13 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −11,445 | 314,662 | ||
| 2025-10-09 | Raben David Chief Medical Officer | Option exercise 10b5-1 | +22,000 | $3.79 | $83K | 57,497 |
| 2025-10-09 | Raben David Chief Medical Officer | Sale 10b5-1 | −22,000 | $18.45 | $406K | 35,497 |
| 2025-10-09 | Raben David Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −22,000 | 128,870 | ||
| 2025-10-09 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 | +6,415 | $3.79 | $24K | 151,770 |
| 2025-10-09 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −6,415 | $18.23 | $117K | 145,355 |
| 2025-10-09 | Hyep Ivan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,415 | 116,584 | ||
| 2025-10-08 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 | +5,627 | $3.79 | $21K | 150,982 |
| 2025-10-08 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −5,627 | $18.21 | $102K | 145,355 |
| 2025-10-08 | Hyep Ivan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,627 | 122,999 | ||
| 2025-10-07 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 | +18,244 | $3.79 | $69K | 163,599 |
| 2025-10-07 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −18,244 | $18.22 | $332K | 145,355 |
| 2025-10-07 | Hyep Ivan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −18,244 | 128,626 | ||
| 2025-10-07 | Cohlhepp Ryan President and COO | Option exercise 10b5-1 | +8,000 | $3.79 | $30K | 213,541 |
| 2025-10-07 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −8,000 | $18.06 | $144K | 205,541 |
| 2025-10-07 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −2,900 | $18.06 | $52K | 202,641 |
| 2025-10-07 | Cohlhepp Ryan President and COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,000 | 165,334 | ||
| 2025-10-06 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 | +6,514 | $3.79 | $25K | 151,869 |
Page 10 of 14 · 276 trades